doi: 10.4103/0976-500X.77118.
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
Affiliations
- PMID: 21701650
- PMCID: PMC3117573
- DOI: 10.4103/0976-500X.77118
Item in Clipboard
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
J Pharmacol Pharmacother.
2011 Jan.
No abstract available
Conflict of interest statement
Similar articles
-
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.Nat Rev Drug Discov. 2010 Nov;9(11):883-97. doi: 10.1038/nrd3248. Epub 2010 Oct 29. Nat Rev Drug Discov. 2010. PMID: 21031003 Review.
-
Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.J Neurosci Res. 2020 Mar;98(3):524-536. doi: 10.1002/jnr.24509. Epub 2019 Aug 5. J Neurosci Res. 2020. PMID: 31385341 Review.
-
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.Core Evid. 2011;6:13-21. doi: 10.2147/CE.S10101. Epub 2011 Jan 6. Core Evid. 2011. PMID: 21468239 Free PMC article.
-
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21. Proc Natl Acad Sci U S A. 2011. PMID: 21177428 Free PMC article.
-
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671. Expert Opin Pharmacother. 2010. PMID: 20408749
Cited by
-
Immunological function of sphingosine 1-phosphate in the intestine.Nutrients. 2012 Mar;4(3):154-66. doi: 10.3390/nu4030154. Epub 2012 Mar 6. Nutrients. 2012. PMID: 22666543 Free PMC article. Review.
-
Potential Drug Targets for Ceramide Metabolism in Cardiovascular Disease.J Cardiovasc Dev Dis. 2022 Dec 2;9(12):434. doi: 10.3390/jcdd9120434. J Cardiovasc Dev Dis. 2022. PMID: 36547431 Free PMC article. Review.
-
Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.BMC Neurol. 2020 May 29;20(1):218. doi: 10.1186/s12883-020-01804-2. BMC Neurol. 2020. PMID: 32471473 Free PMC article.
-
Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation.Sci Rep. 2019 Dec 4;9(1):18329. doi: 10.1038/s41598-019-54877-6. Sci Rep. 2019. PMID: 31797978 Free PMC article.
-
Signaling through the S1P-S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment.Cells. 2021 Nov 18;10(11):3217. doi: 10.3390/cells10113217. Cells. 2021. PMID: 34831439 Free PMC article. Review.
References
-
- Noseworthy JH, Lucchinetti CF, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–52. - PubMed
-
- Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–31. - PubMed
-
- Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci. 2001;22:117–39. - PubMed
-
- Vasiliou S. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drugs Today. 2010;46:315–25. - PubMed
-
- FDA approves first oral drug to reduce MS relapses. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm [cited in 2010]
LinkOut - more resources
Full Text Sources